Cholera
Conditions
Keywords
Vaccination, Contagious Diseases, Tropical Medicine, Infectious Diseases
Brief summary
The primary objective of this study is to evaluate the antibody response to the cholera vaccine, Vaxchora®, in healthy subjects. Investigators also seek to evaluate additional markers of the adaptive immune response including plasmablasts, activated B cells, memory B cells, and T cell responses in healthy subjects receiving cholera vaccine, produce monoclonal antibodies against cholera, and evaluate the safety and reactogenicity in healthy subjects receiving cholera vaccine.
Detailed description
Vibrio cholerae causes an acute diarrheal disease responsible for more than 100,000 deaths and affects an estimated 3 to 5 million people annually. Recent epidemics in Haiti and Africa illustrate the continued reach of this pathogen. Across the globe, one billion people lack access to safe drinking water and are vulnerable to cholera. The increasing disease burden, and emergence of more virulent strains, suggest that more aggressive approaches to preventing cholera are needed. This includes renewed efforts to understand the mechanism of protective immunity against cholera and to improve the protective efficacy of current cholera vaccines. Vaxchora is a live attenuated cholera vaccine that protects against some cholera strains. It has been approved by the FDA since June 2016. Since October, 2016, this vaccine has been recommended for certain travelers 18 through 64 years of age going to cholera-affected areas. The purpose of this study is to look at the immune responses to the FDA approved cholera vaccine (Vaxchora®). This study aims to enroll 50 participants who will receive the Vaxchora live cholera vaccine, of whom 30 will undergo two procedures for small intestinal biopsies: one at screening and the other post vaccination (25 participants at Day 29 and 5 participants at day 90) by an upper endoscopy biopsy (EGD).
Interventions
DRUGVaxchora
Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
Sponsors
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* Capable of informed consent and provision of written informed consent before any study procedures * Capable of attending all study visits according to the study schedule * Are in good health, as determined by medical history and targeted physical exam related to this history * Female subjects of childbearing age must have a negative urine pregnancy test before study vaccination, and must use two forms of contraception to avoid pregnancy within one month of Vaxchora administration
Exclusion criteria
* Have an acute illness within 72 hours before vaccination * Have any acute or chronic medical condition that, in the opinion of the principal investigator, would make vaccination unsafe or interfere with the evaluation of immune response to study vaccination * Have a suppressed immune system as a result of illness, immunosuppressive medication, chemotherapy, or radiation therapy within 3 years prior to study vaccination * Have taken oral or parenteral corticosteroids of any dose within 30 days before study vaccination * Reside with individuals under the age of 2 or with an immunocompromised individuals * Have a known history of autoimmune disease * Have a history of Guillain-Barre Syndrome * Have plans to receive any vaccine from 28 days prior to study vaccination until Day 29 * Has previously received a cholera vaccine or have a known history of V. Cholerae. * Have donated blood or blood products within 56 days before study vaccination, plan to donate blood at any time during the 56-day duration of subject study participation, or plan to donate blood within 56 days after the last blood draw * Have known hypersensitivity or allergy to any component of the vaccine or history of anaphylaxis with a vaccine or vaccine component * Have allergy to tetracycline and/or ciprofloxacin * Are pregnant or breastfeeding or plan to within one month of vaccination * Traveled to a cholera endemic area and had traveler's diarrhea in the previous 5 years * Have abnormal stool pattern (fewer than 3 stools/ week or greater than 2 stools/ day) or regular use of laxatives in the last 6 months * Have current or recent antibiotic use in the past 14 days * Are healthcare workers who have direct contact with patients who are immunocompromised, have unstable medical conditions, or are under the age of 2 * Are childcare caregivers who have direct contact with children who are 2 years or younger * Are employed in the food industry * Have received any vaccine within the previous 21 days * History of bleeding disorders or current use of warfarin, aspirin, heparin, nonsteroidal anti-inflammatory drugs (NSAIDs) or other blood thinner/ anticoagulant medications in the past week for subjects undergoing intestinal biopsies. * Use of benzodiazepines or narcotics for subjects undergoing intestinal biopsies 4 weeks prior to the procedure * Any contraindications to endoscopy/concerns of the anesthesiologist for subjects who agree for esophagogastroduodenoscopy (EGD)/biopsies * Body mass index (BMI) \> 35 kg/m\^2 * Have a diagnosis of any small bowel disease. This includes but is not limited to inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, or microscopic colitis), small bowel obstruction, celiac disease, h/o small bowel resection, small bowel lymphoma, Whipple's disease, primary intestinal lymphangiectasis, abdominal radiation. * Current medications for the treatment of gastroesophageal reflux disease (GERD) or dyspepsia * History of Helicobacter pylori (H. pylori) infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of Antibody Titers in Serum | Day 1 (pre-vaccination), Day 29 | Antibody response is evaluated as the level of antibody titers in serum. Higher vibriocidal antibody titers indicate greater protection against cholera. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasmablast Levels | Day 1 (pre-vaccination), Day 8, Day 29 | Plasmablasts are collected via blood draw and isolated and assessed for counts by the study team. |
| Activated B Cell Levels | Day 1 (pre-vaccination), Day 8, Day 29 | Activated B cells are collected via blood draw and isolated and assessed for counts by the study team. |
| Memory B Cell Levels | Day 1 (pre-vaccination), Day 29 | Memory B cells are collected via blood draw and isolated and assessed for counts by the study team. The level of memory B cells is evaluated as the percentage of antigen specific immunoglobulin (Ig) secreting cells divided by the total Ig secreting cells. |
| Number of Monoclonal Antibodies Produced Per Participant | Day 8 | The number of antigen-specific monoclonal antibodies (mAbs) was assessed in a subset of participants on Day 8 post-vaccination. Peripheral blood mononuclear cells (PBMCs) were isolated, and antigen-specific plasmablasts were single-cell sorted using fluorescently labeled V. cholerae antigens (e.g., CTB and LPS). Paired immunoglobulin heavy and light chain variable regions were amplified by RT-PCR, cloned into expression vectors, and expressed in mammalian cells. The number of unique antigen-specific monoclonal antibodies was determined by binding assays (e.g., ELISA). |
| Number of Cholera Toxin B (CTB) Specific Monoclonals and Lipopolysaccharide (LPS) Specific Monoclonal Antibodies Per Participant | Day 8 | The monoclonal antibodies obtained were characterized as cholera toxin B (CTB) specific monoclonals and lipopolysaccharide (LPS) specific monoclonals. The characterization of monoclonal antibodies against V. cholerae is assessed in a subset of participants. |
| Number of Adverse Events | Up to Day 8, Up to Day 29 | The number of solicited and unsolicited adverse events were collected. |
| Number of Serious Adverse Events | Up to Day 365 | The number of serious adverse events were collected during the duration of the study. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORNadine Rouphael, MD
Emory University
Participant flow
Recruitment details
Participants were recruited at The Hope Clinic of Emory University in Atlanta, Georgia, USA. Participant enrollment began August 29, 2017 and follow up for the Day 29 study visit concluded on December 10, 2024.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 34 Participants |
| Age, Continuous | 33.9 years STANDARD_DEVIATION 8.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 33 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 11 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 20 Participants |
| Region of Enrollment United States | 34 Participants |
| Sex/Gender, Customized Female | 17 Participants |
| Sex/Gender, Customized Male | 13 Participants |
| Sex/Gender, Customized Unknown/Not reported | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 34 |
| other Total, other adverse events | 19 / 34 |
| serious Total, serious adverse events | 1 / 34 |
Outcome results
None listed